The Screen · Consumer Defensive · Household & Personal Products
Edgewell Personal Care Company
EPC · the NYSE · USD · Market cap $1.3B · 6,200 employees
Edgewell Personal Care Company, together with its subsidiaries, manufactures and markets personal care products worldwide.
FAIL · Does not pass the screen
27.94 USD
At the last full screen 2026-09-01
Screened 2026-09-01 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Edgewell Personal Care Company holds its Distribution at $27.94. The statistical read favours the sellers, held for 12 days.
As held on the ledger · 2026-09-01
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 12 days
Price at the screen
$27.94
Valuation
N/A trailing · 13.88 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.40
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
37.61%
Below 33%
Interest-bearing debt is 37.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.68%
Below 49%
Money owed to the company is 9.7% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-01 screen. The gold marker is the market price at the same screen. The price runs 9.6% above the base estimate.
Third-party analyst targets: 6 covering, consensus None. The average target sits +15% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Daily shaves and lotions hide weak returns
Think of the bathroom cabinet that gets restocked every few months with razors, sun cream and feminine care items. Edgewell makes those staples yet posts revenue growth of just 1 percent, a negative profit margin and negative return on equity. The shares sit above our fair value estimate with no margin of safety, so we pass.
Forward earnings trade at 14.5 times while the business shows no pricing power or scale advantage. Analyst targets cluster around current levels but offer no cushion against the thin results already on show. Ethical checks clear, yet the numbers do not.
Defensive labels can mask cyclical volume pressure and brand erosion in a crowded aisle. Without a visible moat or path back to positive returns, the valuation leaves little room for error. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EPC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-28Markup · changed$28.47-4.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-27Distribution$29.66+29.3%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 29.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-18Distribution$22.94+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-03Distribution$22.94+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$22.94Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
